JR Lisse, M Perlman, G Johansson, JR … - Ann Intern Med, 2003 - Am Coll Physicians Patients: 5557 patients (mean age, 63 years) with a baseline diagnosis of
osteoarthritis of the knee, hip, hand, or spine. Intervention: Rofecoxib, 25
mg/d, or naproxen, 500 mg twice daily. Use of routine medications, ... Cited by 97 - Related articles - BL Direct - All 7 versions
KE Truitt, RS Sperling, WH Ettinger Jr, M … - Aging (Milan, Italy), 2001 - ncbi.nlm.nih.gov This 6-week study was conducted to test the efficacy, safety, and tolerability
of rofecoxib (a selective COX-2 inhibitor) compared to nabumetone (a
non-selective NSAID) and placebo in osteoarthritis (OA) patients aged 80 ... Cited by 52 - Related articles - BL Direct
- ►bmj.com [PDF] CJ Hawkey, L Laine, T Simon, H Quan, S … - British Medical Journal, 2003 - gut.bmj.com Page 1. doi:10.1136/gut.52.6.820 2003;52;820-826 Gut CJ Hawkey, L Laine,
T Simon, H Quan, S Shingo and J Evans randomised, double ... Cited by 42 - Related articles - BL Direct - All 7 versions
AJ Kivitz, MW Greenwald, SB Cohen, AB Polis … - Journal of the American Geriatrics Society, 2004 - interscience.wiley.com It is also possible that your web browser is not configured or not able to
display style sheets. In this case, although the visual presentation will be
degraded, the site should continue to be functional. We recommend using the ... Cited by 22 - Related articles - BL Direct - All 5 versions
K Saag, D van der Heijde, C Fisher, A Samara … - Archives of Family Medicine, 2000 - archfami.highwire.org Methods Two randomized, double-blind, parallel-group studies in patients with OA
of the knee or hip were conducted using identical entry criteria and end points.
A 6-week placebo-controlled trial in 736 patients compared 12.5 and 25 mg ... Cited by 79 - Related articles - BL Direct - All 3 versions
A Gibofsky, GW Williams, F McKenna, JG Fort - Arthritis Care & Research - interscience.wiley.com It is also possible that your web browser is not configured or not able to
display style sheets. In this case, although the visual presentation will be
degraded, the site should continue to be functional. We recommend using the ... Cited by 33 - Related articles - BL Direct - All 3 versions
PP Geusens, K Truitt, P Sfikakis, PL Zhao, L … - Scandinavian journal of rheumatology, 2002 - informahealthcare.com Objective: To evaluate the eYcacy and tolerability of rofecoxib 25mg and 50mg
once daily versus placebo and naproxen 500mg twice daily in patients with RA.
Methods: Eligible patients were randomized (double-blind) to placebo (n ... Cited by 34 - Related articles - BL Direct - All 9 versions
- ►oxfordjournals.org W Bensen, A Weaver, L Espinoza, WW Zhao, W … - Rheumatology, 2002 - Br Soc Rheumatology Methods. This multi-centre, randomized, double-blind, placebo-controlled trial
compared the efficacy and safety of valdecoxib 10 mg (n=209), 20 mg (n=212) or
40 mg once daily (qd) (n=221) with naproxen 500 mg bid (n=226) or placebo ... Cited by 91 - Related articles - BL Direct - All 5 versions
GW Cannon, JR Caldwell, P Holt, B McLean, … - Arthritis and rheumatism, 2000 - ncbi.nlm.nih.gov OBJECTIVE: To compare the clinical efficacy of rofecoxib, a specific inhibitor
of cyclooxygenase 2 (COX-2), with that of diclofenac in patients with
osteoarthritis (OA) and to evaluate the safety and tolerability of ... Cited by 98 - Related articles
R Myllykangas-Luosujärvi, HS Lu, SL Chen, … - Scandinavian Journal of Rheumatology, 2002 - informahealthcare.com 1Kuopio University Hospital, Kuopio, Finland, 2Ren Min Hospital, BMU, Beijing,
China, 3Ren Ji Hospital, Shanghai, China, 4University Hospital Kuala Lumpur,
Kuala Lumpur, Malaysia, 5Phil. Gen. Hospital, Manila, Philippines, ... Cited by 16 - Related articles - BL Direct - All 4 versions
